Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function

Current Opinion in Lipidology

Volumn 9, Issue 6, 1998, Pages 575-586

  Blum, Arnon ^a   Cannon III, Richard O ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; LIPOPROTEIN; NITRIC OXIDE; RALOXIFENE;

ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; BREAST CANCER; CARDIOVASCULAR EFFECT; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FIBRINOLYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR PHYSIOLOGY; ESTROGENS; FEMALE; HUMANS; LIPOPROTEINS; MALE; RECEPTORS, ESTROGEN;

EID: 0032406002     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199812000-00010     Document Type: Review

References (97)

1. National Center for Health Statistics. Vital statistics of the United States, 1989. Vol. II: mortality. Part A. Washington, DC: Government Printing Office DHHS Publication (PHS); 1993. pp. 93-1101.
2. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105-1110.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102-1109.
4. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: 10-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325:756-762.
5. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47-63.
6. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992: 117:1038-1041.
7. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330:1062-1071.
8. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-1593.
9. The Writing Group for the PEPI Trial. Effects of estrogen or estrogeniprogestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995; 273:199-208.
10. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, et al., for the PEPI Investigators. Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. Circulation 1998; 97:979-986. Postmenopausal oestrogen therapy, with or without concomitant progestin regimens, produces consistent and sustained reductions in plasma lipoprotein (a) concentrations.
11. Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennam KB. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997; 157:1186-1192. Oestrogen lowers LDL cholesterol levels to a lesser degree than pravastatin but with additive effects when the therapies are combined.
12. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337:595-601. In postmenopausal women with hypercholesterolemia, therapy with oestrogen plus progestin significantly lowers LDL cholesterol and lipoprotein (a) levels. Hormone therapy may be an effective alternative to treatment with simvastatin, especially in women with normal triglyceride levels.
13. Furchgott RF. Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 299:373-376.
14. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.
15. Nathan C, Xie Q-W. Nitric oxide synthase: roles, tolls, and controls. Cell 1994; 78:915-918.
16. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994; 89:1943-50.
17. Karas RH, Baur WE, van Eickles M, Mendcelsohn ME. Human vascular smooth muscle cells express an estrogen receptor isoform. FEBS Letters 1995; 377:103-108.
18. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996; 94:1402-1407.
19. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of coronary arteries. J Am Coll Cardiol 1992; 20:452-457.
20. Keaney JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17β-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994; 89:2251-2259
21. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90:786-791.
22. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89:2545-2551.
23. Roque M, Heras M, Roig E, Masotti M, Rigol M, Betriu A, et al. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol 1998; 31:139-143. Early after transdermal oestrogen administration, endothelium-dependent coronary vasomotion is improved in postmenopausal women with angina and normal coronary arteries.
24. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121:936-941.
25. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Estradiol acutely attenuates coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994; 89:52-60.
26. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelium-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994; 73:951-952.
27. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, e tal. 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92:24-30.
28. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO III. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997; 96:2795-2801. The effects of estradiol at physiological concentrations on endothelium-dependent coronary vasodilator responsiveness in postmenopausal women are mediated by enhanced bioavailability of nitric oxide, which may be responsible in part for the cardioprotective effects of oestrogen.
29. Best PJM, Berger PB, Miller VM, Lerman A. The effects of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998; 128:285-288. Oestrogen replacement therapy results in an increased ratio of nitric oxide to endothelin-1. This may be one mechanism by which oestrogen provides cardiovascular benefit.
30. Ylikorkala O, Orpana A, Puolakka J, Pyorala T, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995; 80:3384-3387.
31. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Upregulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 1995; 360:291-293.
32. Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995; 214:847-855.
33. Caulin-Glaser TL, Garcia-Cardena G, Sarrel P, Sessa W, Bender J. The effect of 17β-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca ' mobilization [abstract]. Circulation 1994; 90 (Suppl 1):1-30.
34. Venema RC, Nishida K, Alexander RW, Harrison DG, Murphy TJ. Organization of the bovine gene encoding the endothelial nitric oxide synthase. Biochim Biophys Acta 1993; 1218:413-420.
35. Kleinen H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene. Analysis of the transcription factors involved. Hypertension 1998; 31:582-588.
36. De Caterina R, Libby P, Peng HB, Thannickai VJ, Rajarashisth TB, Gimbrone MA, et al. Nitric oxide decreases cytokine-induced activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60-68.
37. Peng HB, Rajarashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene expression in vascular endothelial cells. J Cell Chem 1995; 270:17050-17055.
38. Zeiher AM, Fisslthaler B, Schray-Ulz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein-1 in cultured human endothelial cells. Circ Res 1995; 76:980-986.
39. Berliner PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
40. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-1874.
41. Sack MN, Rader DJ, Cannon RO III. Estrogen and inhibition of oxidation of low density lipoproteins in postmenopausal women. Lancet 1994; 343:269-270.
42. Caulin-GlaserT, Watson CA, Pardi R, Bender JR. Effects of 17β-estradiol on cylokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98:36-42.
43. Koh KK, Bui MN, Mincemoyer R, Cannon RO III. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997; 80:1505-1507. Oestrogen has anti-inflammatory effects which are manifested by a reduction in the level of soluble cell adhesion molecules.
44. Caulin-Glaser T. Farrell WJ, Pfau SE, Zaret B, Bunger K, Serato JR, et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998; 31:1555-1560.
45. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 1991; 261:R1022-R1027.
46. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24:1757-1761.
47. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97:1234-1238. Long-term combined oral hormone replacement therapy is without beneficial effects on endothelial vasomotor function in healthy postmenopausal women. This supports the view that progesterone may attenuate the beneficial effects of unopposed oestrogen replacement.
48. McCrohon JA, Adams MR, McCredle RJ, Robinson J, Pike A, Abbey M, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy postmenopausal women. Clin Endocrinol. 1996; 45:435-441.
49. The Coronary Drug Project Research Group. The Coronary Drug Project. JAMA 1973; 226:652-657.
50. Robinson RW, Higano N, Cohen WD. Long-term effects of high dosage estrogen therapy in men with coronary heart disease. J Chronic Dis 1963; 16:155-161.
51. Stamler J, Katz LN, Pick R, Lewis LA, Page IH, Pick A, et al. Effects of long-term estrogen therapy on serum cholesterol-lipid-lipoprotein levels and on mortality in middle-aged men with previous myocardial infarction. Circulation 1960; 22:658.
52. Marmorston J, Moore FJ, Kuzma OT, Magidson O, Weiner J. Effects of premarin on survival in men with myocardial infarction. Proc Soc Exp Biol 1960; 105:618.
53. Damewood MD, Bellantoni JJ, Bachorik PS, Kimball AW Jr, Rock JA. Exogenous estrogen effect on lipid/lipoprotein cholesterol in transsexual males. J Endocrinol Invest 1989; 12:449-454.
54. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995; 92:3431-3435.
55. Kawano H, Motoyama T, Kugiyama K, Hirashima O, Ohgushi M, Fujii H, et al. Gender difference in improvement of endothelium-dependent vasodilation after estrogen supplementation. J Am Coll Cardiol 1997; 30:914-919.
56. New G, Timmins KL, Duffy SJ, Tran B, O'Brien R, Harper R, Meredith IT. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997; 29:1437-1444. Long-term oestrogen therapy appears to improve vascular function in male to female transsexuals and occurs despite higher triglyceride levels and the presence of small, dense LDL cholesterol. The beneficial effects of oestrogen are not gender specific, nor solely mediated through endothelium-derived nitric oxide.
57. McCrohon JA, Walters WAW, Robinson JTC, McCredie RJ, Turner L, Adams MR, et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997; 29:1432-1426.
58. Kim YD, Chen B, Beauregard J, Kouretas P, Thomas G, Farhat MY, et al. 17β-estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation 1996; 94:2901-2908.
59. Node K, Kitakaze M, Kosaka H, Minamino T, Funaya H, Hori H. Amelioration of ischemia and reperfusion induced myocardial injury by 17β-estrdaiol. Circulation 1997; 96:1953-1963. 17β-oestradiol reduced both myocardial infarct size and the occurrence of ischemia- and reperfusion-induced ventricular arrhythmias, which appear to be mediated by nitric oxide and the opening of calcium-activated potassium channels in canine hearts.
60. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effects of estrogen on exercise-induced myocardial ischemia in women with CAD. Lancet 1993; 342:133-136.
61. Rosano GMC, Caixeta AM, Chierchia S, Arie S, Lopez-Hidalgo M, Periera WI, et al. Short-term anti-ischemic effect of 17β-estradiol in postmenopausal women with coronary artery disease. Circulation 1997; 96:2837-2841. 17β-oestrogen reduces the degree of pacing-induced myocardial ischemia in postmenopausal patients with coronary artery disease. The reduction of pacing-induced coronary sinus pH shift is consistent with an anti-ischemic effect of the hormone and is not caused by preconditioning, as is evident by the absence of improvement after placebo.
62. Alpaslan M, Shimokawa H, Kuroiwa-Matsumoto M, Harasawa Y, Takeshita A. Short-term estrogen administration ameliorates dobutamine-induced myocardial ischemia in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1997; 30:1466-1471. Oestrogen has short-term anti-ischemic effects on myocardial ischemia induced by increased myocardial oxygen demand in postmenopausal women with coronary artery disease.
63. Sullivan TR, Karas RH, Aronovitz M, Faller GT, Ziar JP. Smith JJ, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995; 96:2482-2488.
64. Chen S-J, Li H, Durand J, Oparil S, Chen Y-F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996; 93:577-584.
65. Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW. Estradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993; 109:612-617.
66. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997; 95:1768-1772. Oestrogen accelerates functional endothelial recovery after barotraumatic deendothelializing injury.
67. Geary R, Adams MR, Benjamin ME, Williams JK. Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimai hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys. J Am Coll Cardiol 1998; 31:1158-1164. In the circumstance of transmural injury to arteries of primates with preexisting atherosclerosis, oestrogen does not suppress arterial neointimal or structural responses to injury.
68. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman M, Faxon DP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996; 28:1111-1118.
69. O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29:1-5. Oestrogen replacement therapy was associated with an improved long-term outcome after percutaneous transluminal coronary angioplasty in post-menopausal women.
70. Lupu F. Bergonzelli GF, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13:1090-1100.
71. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study. Circulation 1995; 91:284-290.
72. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-1168.
73. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343:940-943.
74. Gebara OCE, Mitlleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91:1952-58.
75. Koh KK, Mincemoyer R, Bui MN, Csako G. Pucino F, Guetta V, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683-690. Conjugated oestrogen, alone or in combination with progestin therapy, reduced PAI-1 levels by approximately 50% in postmenopausal women and was associated with enhanced systemic fibrinolysis. These findings may partly explain the protective effect of hormone-replacement therapy with respect to coronary artery disease.
76. Foegh ML, Khirabadi BS, Nakanishi T. Vargas R, ramwell PW. Estradiol protects against experimental cardiac transplant atherosclerosis. Transplant Proc 1987; 19:90-95.
77. Cheng LP, Kuwahara M, Jacobsson J, Foegh ML. Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta allografts. Transplantation 1991; 52:967-972.
78. Lou H, Kodama T, Zhao J, Maurice P. Wang YN, Katz N, Foegh ML. Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression. Circulation 1996; 94:3355-3361.
79. Motomura N, Lou H, Hong M, Tsutsumi Y, Mayumi T, Foegh ML. Local administration of estrogen inhibits transplant arteriosclerosis in rat aorta accelerated by topical exposure to IGF-I. Transplant Proc 1997; 29:1118-1120.
80. Koloed KF, Czernin J, Johnson J, Kobashigawa J. Phelps ME, Laks H, Schelbert HR. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomolion. Circulation 1997; 95:600-606.
81. Reis SE, Bhoopalam V, Zell KA, Counihan PJ, Smith AJC, Pham S, Murali S. Conjugated estrogen acutely abolish abnormal cold-induced coronary vasoconstriction in male cardiac allografts. Circulation 1998; 97:23-25. Conjugated oestrogens acutely abolish abnormal cold pressor test-induced coronary artery constriction in male cardiac allografts. This favorable vasomotor effect suggests that oestrogen may prevent inappropriate coronary artery constriction in men with cardiac transplants.
82. Farnsworth NR. Bingel AS, Cordell AS, Crane FA, Fong HHS. Potential value of plants as sources of new antifertility agents. J Pharm Sci 1975; 64:717-754.
83. Hodgson JM, Puddey IB, Beilin LJ, Mori TA, Croft KD. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. J Nutr 1998; 128:728-732.
84. Tikkanen MJ, Wahala K, Ojala S, Vihama V, Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A 1998; 95:3106-3110.
85. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997; 94:14138-14143.
86. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, and estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996; 10:905-912.
87. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Mineral Metabol 1996; 14:1-9.
88. Sato M, Glasebrook AL, Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Mineral Metabol 1995; 12 (Suppl 2):S9-S20.
89. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res 1997; 48:155-163.
90. Guetta V, Lush RM, Figg WD Waclawiw MA, Cannon RO III. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1995; 76:1072-1073.
91. Anzano MA, Peer CW, Smith JM, Muller LT, Shrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 90cis-retinoic acid. J Natl Cancer Inst 1996:88:123-125.
92. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A. Williams DC, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-69.
93. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994; 135:2001-2005.
94. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-1647. Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol but does not stimulate the endometrium.
95. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279:1445-1451.
96. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96:1964-1969. Seventy-five rabbits were ovariectomized and treated with either raloxifene, 17β-estradiol, or placebo. After 45 weeks, the raloxifene group had two-thirds the extent of aortic atherosclerosis as evaluated by the cholesterol content of the proximal inner part of the aorta observed in the placebo group. The oestrogen group had one-third of the aortic atherosclerosis in the placebo group. Raloxifene hydrochloride has a potentially important antiatherogenic effect, analogous to that observed with oestrogen.
97. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclersis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83:721-726. In this primate model of oestrogen deficiency and atherosclerosis, oestrogen, but not raloxifene, reduced coronary artery plaque size.